Case Report: Apremilast for Therapy-Resistant Pemphigus Vulgaris.
T follicular regulatory (Tfr) cell
apremilast
autoimmunity
blistering disorders
pemphigus vulgaris (PV)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
07
2020
accepted:
05
10
2020
entrez:
16
11
2020
pubmed:
17
11
2020
medline:
17
7
2021
Statut:
epublish
Résumé
In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3',5'-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in hematological and auto-inflammatory disorders. A class of enzymes called phosphodiesterases (PDEs) control intracellular cAMP levels. In pemphigus, cAMP levels increase following IgG binding to Dsg3. This appears to be a mechanism to preserve epithelial integrity. To determine whether apremilast, an inhibitor of the PDE4 normally used in psoriasis, may be of benefit in the blistering skin disorder pemphigus. Here we report of a 62 years old patient with chronic debilitating and recalcitrant pemphigus not responding to several previous treatments, who received treatment with apremilast over a period of 32 weeks. Desmoglein autoantibody levels were assessed by Enzyme-linked Immunosorbent Assay (ELISA), whereas disease severity and quality of life were assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In an attempt to explain the effects of apremilast in pemphigus, peripheral blood mononuclear cells (PBMCs) were analyzed for the duration of treatment by flow cytometry for the distribution of specialized T cell subsets. The frequencies of circulating T helper (Th) 1, Th2, Th17, Th17.1 and T follicular helper (Tfh) 1, Tfh2, Tfh17, and Tfh17.1 were analyzed by CCR6, CXCR3, and CXCR5 expression of CD4 In response to apremilast treatment, Dsg-specific autoantibody titers decreased, blistering ceased and lesions healed, showing a long-lasting effect. While the frequencies of most of the Th and Tfh cell subsets remained unchanged, we observed a continuous increase in Treg and Tfreg cell levels. Our findings are encouraging and warrant extension of the beneficial effect of PDE4 inhibition on a larger cohort of pemphigus patients.
Sections du résumé
Background
In pemphigus, elucidating the disease-causing immune mechanism and developing new therapeutic strategies are needed. In this context, the second messenger 3',5'-cyclic adenosine monophosphate (cAMP) is gaining attention. cAMP is important in hematological and auto-inflammatory disorders. A class of enzymes called phosphodiesterases (PDEs) control intracellular cAMP levels. In pemphigus, cAMP levels increase following IgG binding to Dsg3. This appears to be a mechanism to preserve epithelial integrity.
Objectives
To determine whether apremilast, an inhibitor of the PDE4 normally used in psoriasis, may be of benefit in the blistering skin disorder pemphigus.
Methods
Here we report of a 62 years old patient with chronic debilitating and recalcitrant pemphigus not responding to several previous treatments, who received treatment with apremilast over a period of 32 weeks. Desmoglein autoantibody levels were assessed by Enzyme-linked Immunosorbent Assay (ELISA), whereas disease severity and quality of life were assessed by the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS). In an attempt to explain the effects of apremilast in pemphigus, peripheral blood mononuclear cells (PBMCs) were analyzed for the duration of treatment by flow cytometry for the distribution of specialized T cell subsets. The frequencies of circulating T helper (Th) 1, Th2, Th17, Th17.1 and T follicular helper (Tfh) 1, Tfh2, Tfh17, and Tfh17.1 were analyzed by CCR6, CXCR3, and CXCR5 expression of CD4
Results
In response to apremilast treatment, Dsg-specific autoantibody titers decreased, blistering ceased and lesions healed, showing a long-lasting effect. While the frequencies of most of the Th and Tfh cell subsets remained unchanged, we observed a continuous increase in Treg and Tfreg cell levels.
Conclusion
Our findings are encouraging and warrant extension of the beneficial effect of PDE4 inhibition on a larger cohort of pemphigus patients.
Identifiants
pubmed: 33193415
doi: 10.3389/fimmu.2020.588315
pmc: PMC7653172
doi:
Substances chimiques
Phosphodiesterase 4 Inhibitors
0
Thalidomide
4Z8R6ORS6L
apremilast
UP7QBP99PN
Types de publication
Case Reports
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
588315Informations de copyright
Copyright © 2020 Meier, Holstein, Solimani, Waschke and Ghoreschi.
Références
Front Immunol. 2018 Jul 18;9:1662
pubmed: 30072998
Immunity. 2011 Jan 28;34(1):108-21
pubmed: 21215658
J Immunol. 2010 Dec 1;185(11):6831-8
pubmed: 21037102
J Immunol. 2009 Apr 1;182(7):4017-24
pubmed: 19299699
Rheumatology (Oxford). 2019 Dec 1;58(12):2240-2250
pubmed: 31209492
Arthritis Res Ther. 2010;12(3):R107
pubmed: 20525198
Blood. 2016 Dec 22;128(25):2886-2890
pubmed: 27756749
J Invest Dermatol. 2016 Nov;136(11):2211-2220
pubmed: 27388992
Front Immunol. 2019 Jun 25;10:1418
pubmed: 31293582
Nat Immunol. 2016 Dec;17(12):1436-1446
pubmed: 27695002
Drugs. 2018 Oct;78(15):1527-1548
pubmed: 30238396
J Invest Dermatol. 2018 Jan;138(1):32-37
pubmed: 29037765
Science. 2016 Jul 8;353(6295):179-84
pubmed: 27365313
Sci Rep. 2017 Jun 15;7(1):3579
pubmed: 28620161
PLoS One. 2016 Feb 12;11(2):e0148919
pubmed: 26872212
J Allergy Clin Immunol. 2020 Nov;146(5):1070-1079.e8
pubmed: 32311391
Cell Mol Life Sci. 2005 Jun;62(11):1198-220
pubmed: 15798894
Nat Rev Dis Primers. 2017 May 11;3:17026
pubmed: 28492232
Eur J Dermatol. 2018 Jun 1;28(3):413-414
pubmed: 29619999